Project Grant R61HL171786
Award Date
9/6/24
Completion Date
7/31/26
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $728,577 to investigate the role of purinergic signaling in idiopathic pulmonary fibrosis (IPF), a devastating lung disease. The research aims to elucidate how extracellular ATP and the fibroblast-specific ATP receptor P2RX4 regulate profibrotic pathways in lung fibroblasts, with the goal of validating P2RX4 as a novel therapeutic target for IPF. The 4-year...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how tissue factors in the lung alter the inflammatory response to viral infections, leading to the loss of alveolar type 2...
This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
This federal Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (ORIP) under CFDA 93.351 will provide $246,000.00 from July 15, 2025 to April 30, 2027 to The Regents of the University of California, San Francisco (UCSF) to characterize a novel mouse model linking sphingolipid metabolism to multi-organ fibrosis. The project aims to: 1) Characterize the spectrum of organs affected by fibrosis and sphingolipid changes in the S1P lyase (SPL)...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...
This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...
This Project Grant award of $325,080 from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of aging and metabolic dysfunction in disrupting alveolar epithelial progenitor cell function in pulmonary fibrosis. The funded project will utilize an aged mouse model of idiopathic pulmonary fibrosis (IPF) to characterize the impact of aging on mitochondrial quality control and metabolic changes in...